Continued Access to RXDX-105 | NCT03784378 | Trialant

Continued Access to RXDX-105 | NCT03784378 | Trialant

Arms/Interventions Module

Interventions

Name	Type	Description	Arm Group Labels	Other Names
RXDX-105	Drug	RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Evaluation during treatment/intervention	Safety assessments will be performed as standard of care and as clinically indicated. This will include monitoring of adverse events, including serious adverse events including CTCAE grading.	Through study completion, up to five years.

Contacts/Locations Module

Condition Browse Module